Science Corp. raises $230 million to commercialize its PRIMA retinal implant
The Series C values the company at about $1.5 billion and funds PRIMA's launch plus new clinical programs.
Science Corporation has closed an oversubscribed $230 million Series C with investors including Lightspeed Venture Partners, Khosla Ventures, Y Combinator and IQT. The round brings total funding to about $490 million, and reports value the company at about $1.5 billion. The money will fund commercialization of PRIMA, its wireless retinal implant for advanced macular degeneration, and move other programs into the clinic.
PRIMA was awaiting an FDA decision. It later received a CE mark and launched in Europe (our coverage).
Learn more: Visual prosthesis · Science Corp.